Colorectal Cancer Clinical Trials in Tennessee

Showing 201-220 of 312 trials

A Study to Evaluate the Safety, Tolerability, and Activity of TAK-931 in Participants With Metastatic Pancreatic Cancer, Metastatic Colorectal Cancer, and Other Advanced Solid Tumors

NCT03261947

The purpose of this study is to confirm the safety and tolerability of TAK-931 in a cohort of Western participants with metastatic solid tumors and to evaluate the anti-tumor activity of TAK-931 in participants with metastatic pancreatic cancer, colorectal cancer (CRC), squamous esophageal cancer (sqEC), and squamous non-small-cell lung cancer (sqNSCLC).

Metastatic Pancreatic CancerColorectal CancerEsophageal Neoplasms+1 more

Millennium Pharmaceuticals, Inc.101 participantsStarted Oct 2017

Denver, Colorado, United States • Sarasota, Florida, United States • Minneapolis, Minnesota, United States +7 more locations

COMPLETEDPhase 129 miles

First-in-Human Study of JNJ-74699157 in Participants With Tumors Harboring the KRAS G12C Mutation

NCT04006301

The purpose of this study is to determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) of JNJ-74699157 in participants with advanced solid tumors harboring a kirsten rat sarcoma virus homolog (KRAS) glycine-to-cysteine (G12C) mutation (Part 1: Dose escalation) and to determine the safety and preliminary antitumor activity of JNJ-74699157 at the RP2D regimen in participants with advanced solid tumors harboring a KRAS G12C mutation (Part 2: Dose expansion).

NeoplasmsAdvanced Solid TumorsNon-small Cell Lung Cancer+1 more

Janssen Research & Development, LLC10 participantsStarted Jul 2019

Sarasota, Florida, United States • Tampa, Florida, United States • Nashville, Tennessee, United States +4 more locations

A Study to Evaluate the Safety, Tolerability, and Activity of TAK-931 in Participants With Metastatic Pancreatic Cancer, Metastatic Colorectal Cancer, and Other Advanced Solid Tumors

First-in-Human Study of JNJ-74699157 in Participants With Tumors Harboring the KRAS G12C Mutation

Colorectal Cancer Trials in Other Cities

Radiation Therapy Plus Chemotherapy Followed by Surgery in Treating Patients With Locally Advanced Cancer of the Rectum

A Study Assessing Perfusion Outcomes With PINPOINT® Near Infrared Fluorescence Imaging in Low Anterior Resection

A Multiple Ascending Dose Study of MEDI7247 in Advanced or Metastatic Solid Tumors

Blood and Stool Sample Collection in Subjects Participating in Colorectal Cancer Screening: Act Bold

NKTR-102 in Combination With Cetuximab in Patients With Refractory Solid Tumors (Phase 2a) and Metastatic or Locally Advanced Colorectal Cancer (Phase 2b)

Regorafenib+FOLFIRI Versus Placebo+FOLFIRI as 2nd Line Tx in Metastatic Colorectal Cancer

Phase 2a Study of BAX69 and 5-FU/Leucovorin or Panitumumab Versus Standard of Care in Subjects With Metastatic Colorectal Cancer

Study of CS-7017 in Combination With FOLFIRI in Subjects With Metastatic Colorectal Cancer Who Failed First-Line Therapy

Observational Study of Sub-populations From Cologuard Post-Approval Study (2014-01)

Plasma-based Colorectal Cancer Screening Research & Development

The National CT Colonography Trial

A Study of OMP-305B83 in Subjects With Metastatic Colorectal Cancer

Paired Analysis of Sensitivity for Colorectal Cancer Using COLVERA : PASCAL

Neoadjuvant Chemoradiotherapy and Adjuvant Chemotherapy in Treating Patients Who Are Undergoing Surgical Resection for Locally Advanced Rectal Cancer

Study of Safety and Efficacy of Ribociclib and Trametinib in Patients With Metastatic or Advanced Solid Tumors

Combination Chemotherapy With or Without Chemoembolization in Treating Patients With Colorectal Cancer Metastatic to the Liver (6655)

Validation of Colon Biomarkers for the Early Detection of Colorectal Adenocarcinoma

Safety Study of 90Y-hMN14 to Treat Colorectal Cancer

Other Conditions in Tennessee